fremanezumab sold brand name ajovy medication used prevent migraines given injection common side effect pain redness site side effects include allergic calcitonin generelated peptide antagonist class approved medical use united states european union uk argentina september fremanezumab shown effective adults four attacks per common adverse effects reactions injection site occurred people studies compared placebo hypersensitivity reactions occurred fewer fremanezumab interact antimigraine drugs triptans ergot alkaloids analgesics expected generally low potential interactions metabolized cytochrome fremanezumab fully humanized monoclonal antibody directed calcitonin generelated peptides cgrp alpha precise mechanism action given quarterly interval subcutaneous injection fremanezumab bioavailability highest concentrations body reached five seven days like proteins substance degraded proteolysis small peptides amino acids reused excreted via kidney elimination halflife estimated fremanezumab discovered developed rinat neuroscience acquired pfizer licensed approved us food drug administration september march fremanezumab approved marketing use european drug stillwhen evaluated diseases migraine endogenous substance cgrp implicated pathologycitation needed teva stillwhen developing episodic cluster headache stopped development fremanezumab treatment chronic cluster headache primary endpoint phase iii trial update fremanezumab humanized monoclonal produced using recombinant dna chinese hamster ovary httpsenwikipediaorgwikifremanezumab